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Abstract
Recent state-based studies have shown an increased risk of opioid overdose death in Medicaid 
populations. To explore one side of risk, this study examines indicators of potential opioid 
inappropriate use or prescribing among Medicaid enrollees. We examined claims from enrollees 
aged 18–64 years in the 2010 Truven Health MarketScan® Multi-State Medicaid database, which 
consisted of weighted and nationally representative data from 12 states. Pharmaceutical claims 
were used to identify enrollees (n=359,368) with opioid prescriptions. Indicators of potential 
inappropriate use or prescribing included overlapping opioid prescriptions, overlapping opioid and 
benzodiazepine prescriptions, long acting/extended release opioids for acute pain, and high daily 
doses. In 2010, Medicaid enrollees with opioid prescriptions obtained an average 6.3 opioid 
prescriptions, and 40% had at least one indicator of potential inappropriate use or prescribing. 
These indicators have been linked to opioid-related adverse health outcomes, and methods exist to 
detect and deter inappropriate use and prescribing of opioids.
Keywords
Medicaid; opioids; prescription drugs; overdose
The problem of overdose from prescription medications has emerged as a major public 
health issue in the United States.1 In 2013, drug overdoses killed 43,982 Americans, more 
than the number killed in motor vehicle traffic crashes. Opioid analgesics alone or in 
combination with benzodiazepines or other drugs account for nearly half of all drug 
overdose deaths.2 Misuse or abuse of pharmaceuticals also led to more than 1.4 million 
emergency departments (ED) visits—with over 420,000 involving opioid analgesics in 
2011.3
Studies using administrative data from a limited number of health plans have described 
opioid use generally (such as number of opioid prescriptions received, average daily dose, 
and total days' supply,) and/or potential opioid misuse (such as high daily dosage, 
overlapping opioids, and overlapping opioids and benzodiazepines).4–7 Other studies and 
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government reports have focused on opioid use and misuse specifically among the Medicaid 
population.8–10 This population is of concern because it has, on average, higher levels of 
mental health and substance abuse disorders than the general population9,11 and thus 
potentially greater risk for adverse outcomes with opioids. Indeed, two states have reported 
an increased risk of opioid overdose death in their Medicaid populations.12,13
This study expands the literature in this area by examining multiple indicators of use and 
potential misuse of opioids among Medicaid patients using one of the largest fully-
integrated health insurance claims databases in the United States. The objective is to 
describe the volume of opioid prescribing among Medicaid enrollees, and provide an index 
of measures to describe potential misuse or inappropriate prescribing.
Methods
Data source
We conducted secondary data analyses of the Truven Health MarketScan® Multi-State 
Medicaid database, which consisted of weighted and nationally representative data from 12 
geographically dispersed states. The MarketScan Medicaid database contains standardized, 
fully integrated, enrollee-level de-identified claims across inpatient, outpatient, and 
prescription drug services for both fee-for-services and capitation plans. Our analysis 
primarily drew data from pharmaceutical claims in 2010 for filled prescriptions, which 
included outpatient drug name, therapeutic class, national drug code, days of supply, and 
quantity for about 1.38 million Medicaid enrollees aged 18–64 years. In addition, the 
outpatient service claims and inpatient admission records were used to identify the 
underlying pain diagnoses related to opioid use. Inpatient admission records were employed 
only to identify the diagnoses associated with opioid prescriptions prescribed to enrollees at 
discharge. Drugs administered during hospitalizations were not included. No personal 
identifying information was available in the database, and this study did not require human 
subjects' review.
Study population
From the pharmaceutical claims we identified 3,534,564 opioid prescriptions for the 1.38 
million enrollees aged 18–64 years (Figure 1). We excluded 704,624 opioid prescriptions for 
non-continuously enrolled Medicaid recipients in 2010; 173,125 opioid prescriptions that 
lacked the dispensing information necessary for the calculation of outcome indicators; and 
67,073 opioid prescriptions that were refill prescriptions that could not be linked to their 
original diagnoses. We also excluded 68,642 opioid prescriptions for enrollees under 
institutional long-term-care, and 218,678 for enrollees with a cancer diagnosis in their 
outpatient or inpatient service claims. Cancer diagnosis were based on International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes including 
338.3; 140–172.9; 174–215.9; 217–229.10; and 235–239.9. Finally, roughly 1% (37,405) of 
the opioid prescriptions were for buprenorphine products and were excluded due to their 
primary use for the treatment of opioid dependence (methadone received at narcotic 
treatment centers is excluded by default given that we did not capture narcotic treatment 
center claims). This selection process resulted in 2,265,017 opioid prescriptions for 359,368 
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Medicaid enrollees as our final study population (see Figure 1). A list of opioids analyzed is 
available upon request, and morphine equivalent conversion factors used have been 
previously described.14
Subpopulation with identified diagnoses—To calculate a subset of outcome 
indicators that are specific to certain types of pain, we linked opioid prescription claims to 
the diagnoses on outpatient or inpatient service claims by matching enrollee ID and the date 
of service in these claims. Consistent with the existing literature,15 we linked opioid 
prescriptions to the outpatient services or inpatient discharges that occurred within 14 days 
of the prescription dispense dates. If multiple outpatient or inpatient records existed within 
this interval, we linked to the one that occurred on the day closest to the drug dispense dates. 
When inpatient and outpatient dates of service overlapped, we used the outpatient claims for 
the linkage. Prescription refills were assigned the diagnoses on the original prescriptions. 
We successfully linked 1,772,632 (78.3%) of the 2,265,017 opioid prescriptions to 
diagnoses for 323,879 enrollees (90% of the overall study population). Of the remaining 
21.7% of prescriptions, 19.5% could not be linked because the outpatient services or 
inpatient discharges had occurred more than 14 days prior to the prescription dispensing date 
or in 2009; 2.2% could not be linked because MarketScan did not have the enrollee's 
outpatient service claims.
Outcome indicators
We adapted outcome indicators that had been identified by expert panels and clinical 
guidelines16–22 and validated by their association with abuse of overdose.23–26 These 
indicators captured both general opioid use as well as potential misuse by patients or 
inappropriate prescription practices by providers.
At the enrollee level, indicators of general opioid use included the total number of opioid 
prescriptions, total days' supply of opioids, and medical diagnoses (such as acute pain, other 
pain, or both) associated with opioid prescriptions. Acute pain and other pain diagnoses 
were based on ICD-9-CM codes (Table 1 footnote b and c). Indicators of potential misuse or 
inappropriate prescription practices consisted of: (1) opioid overlap, defined as opioid 
prescriptions that overlap seven or more days (including early refills); (2) opioid and 
benzodiazepine overlap, defined as opioid and benzodiazepine prescriptions that overlap 
seven or more days; (3) high daily opioid dose, defined as a prescribed daily dose of 100 
morphine milligram equivalents (MMEs) or greater; and (4) rapid opioid dose escalation, 
measured as having a 50% or greater increase in mean MMEs per month twice 
consecutively during the year.
Three indicators specific to long-acting/extended-release (LA/ER) prescriptions were 
examined given their elevated risk for addiction and initiation abuse: (1) LA/ER opioid 
prescriptions written for acute pain conditions; (2) overlapping LA/ER opioid prescriptions; 
and (3) LA/ER prescriptions obtained by an opioid “naïve” person, defined as a person who 
had no prescription for an opioid for at least 60 days prior to that for an LA/ER opioid.
At the prescription level, indicators of general opioid use included the number of days' 
supply and the prescribed daily doses for opioid prescriptions for acute, back, and other 
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pain. Back pain included both acute and other back pain and was based on ICD-9-CM codes 
recommended by the American College of Occupational and Environmental Medicine 
(ACOEM) practice guidelines.27 Indicators of potential inappropriate prescription practices 
are the same as those described for enrollees though expressed in number of prescriptions.
Statistical analysis
We calculated the distributions of various levels of usage among all enrollees receiving an 
opioid prescription overall, by sex, and by pain type. The prevalence for indicators of 
potential misuse by patients or inappropriate prescription practices by providers was 
calculated as both a percentage of enrollees and a percentage of prescriptions. We used t-
tests or chi-square tests for comparisons by sex.
Results
Enrollee-level indicators
In the overall study population of Medicaid enrollees with at least one opioid prescription 
(opioid recipients), 74% were female. The mean age of opioid recipients was 41.4 years 
among males and 36.9 years among females (Table 1). Males received on average one more 
opioid prescription than females (males mean = 7.1; females 6.0). More than half of all 
opioid recipients had three or more opioid prescriptions (53%) in 2010. Notably, 7% of the 
study population had 20 or more opioid prescriptions during the data year—with more than 
800 enrollees receiving 50 or more opioid prescriptions (data not shown).
Just under one half of the male recipients (49.4%) received less than 30 total days' supply of 
opioids, and about 37.1% received more than 90 days' supply of opioids in 2010. Among 
women, nearly 60% received less than a 30 days' supply, and 27.1% received more than 90 
days' supply of opioids during 2010. Over 13,000 (14%) male opioid recipients received 
200–364 days of opioids in the past year, and 11,326 (12%) received more than a 365 days' 
supply. For women nearly 27,000 (10%) received 200–364 days, and 21,269 (8%) received 
more than 365 days (data not shown).
We were able to identify the associated medical diagnoses for opioid prescriptions for 90% 
of the overall study population; 22% of the recipients obtained opioids for acute pain 
conditions only; 17.7% received opioids for other pain conditions only; and 29.7% obtained 
opioids for both acute and other pain conditions. Another 20.6% of the recipients received 
opioid prescriptions for diagnoses not included in the lists of acute or other pain conditions 
(e.g., acute pharyngitis, chronic airway obstruction, unspecified dental caries, urinary tract 
infection, and other general symptoms)
The most common indicator of inappropriate use was having an opioid/b enzodiazepine 
overlap (Table 2); 22.6% of the opioid recipients had at least one such event during the 
study period. Seventeen percent of the study population had daily doses of 100 MMEs or 
higher per opioid prescription at least once during the study period, and of those recipients, 
17% had daily doses of 100 MMEs or higher for more than 90 days (data not shown). 
Roughly 1% of the opioid recipients had opioid dose escalation. Overall 40.7% of the opioid 
recipients had at least one indicator of inappropriate use: one-quarter (24.7%) had one 
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indicator, 11% had two and 5% had three. Among those who had LA/ER opioid 
prescriptions, 21.8% received LA/ER opioids for an acute pain condition at least once.
Prescription level indicators
Among the 1,772,632 prescriptions that were linked to diagnoses, about 16.5% of them were 
written for acute pain conditions alone, and a higher proportion (34.9%) were for other pain 
alone. Ten percent were associated with both acute pain and other pain conditions, and 
15.3% were associated with back pain diagnoses. The remaining 38.5% of the prescriptions 
were linked to diagnoses not included in the lists of acute or other pain conditions (as noted 
above).
The mean days' supply for acute, other, and back pain was nine, 20, and 21 days, 
respectively (Table 3). For acute pain, 70.6% of prescriptions were written for nine or fewer 
days, and 14% were written for 30 or more days. The mean daily opioid dose for 
prescriptions for acute pain was higher for men (53.1 MME) than females (49 MME). 
Notably, 9% of prescriptions for acute pain were written for 100 MME per day or more.
For other pain, nearly half (48.4%) of the prescriptions were for 30 or more days. The mean 
daily dose for opioid prescriptions for other pain was higher for males (62 MME) than 
females (52.6 MME). While other pain conditions were treated for longer periods of time 
than acute pain conditions, the average dosage employed was comparable to that used for 
acute pain. For back pain, over half of the prescriptions were for 30 days or more. The mean 
daily dose for back pain was similar to that for other pain at 61.8 MME for males and 51.8 
MME for females.
As for indicators of potential inappropriate prescribing, roughly 30% of opioid prescriptions 
overlapped with other opioid prescriptions, and 30.9% overlapped with a benzodiazepine 
prescription. Among LA/ER opioid prescriptions, a quarter overlapped with other LA/ER 
opioid prescriptions; 5.4% were written for acute pain conditions; and 3.4% were obtained 
by opioid-naïve patients.
Discussion
In 2010, more than 2.2 million opioid prescriptions were written for 359,368 adults without 
cancer diagnoses who were continuously enrolled in Medicaid programs in 12 states. Most 
patients obtained a single opioid prescription without also obtaining prescriptions for 
benzodiazepines or muscle relaxants. Nearly 60% of recipients had opioid prescriptions 
written for less than 30 days. However, signs of potential opioid misuse by patients or 
inappropriate prescribing by providers were evident among this study population. One 
quarter of patients had one indicator of potential misuse of opioids and 16% (or over 
approximately 57,000 patients) had two or more indicators of potential inappropriate use. 
These numbers are substantially higher than a recent analysis examining similar indicators 
among privately insured patients, where 19.2% of patients had one indicator of potential 
inappropriate misuse or prescribing practices and 5.8% had two or more indictors.14 In 
general, this is consistent with findings from previous studies examining opioid use among 
Medicaid patients compared with privately insured patients.7
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It is important to note that most of the prescriptions for opioids appeared to fall within the 
range of appropriate use and standard care. Nevertheless, there is cause for concern. The 
opioid misuse indicators examined in this study have been linked to opioid-related adverse 
health outcomes in other studies. Increased numbers of opioid prescriptions, overlapping or 
early refill prescriptions, dose escalation, and greater days' supply of opioids have all been 
associated with increased risk of clinically recognized abuse.23,24 Higher daily dose has 
been associated with misuse, emergency department visits, and overdoses.24–26 Acute pain 
is not an indication for an LA/ER opioid, and such use is considered inappropriate by 
clinical guidelines19 and yet in this study, 21.8% of those who received a LA/ER opioid, did 
so for acute pain. Further, most LA/ER opioids carry warnings against initiation among 
opioid-naïve patients.
The New York City Department of Health and Mental Hygiene has recommended no more 
than a seven-day supply of opioids for acute pain,28 however, in this study 15.3% of opioid 
prescriptions for acute pain were prescribed for 10–29 days, and 14% were for 30 or more 
days. For severe, acute low back pain specifically, the American College of Occupational 
and Environmental Medicine practice guidelines only recommend opioids on a limited basis, 
with treatment to last no more than two weeks.27 Opioids are not recommended to be used 
for long-term treatment of chronic back pain.29 In this study, over half (51.7%) of opioid 
prescriptions for back pain were written for 30–49 days, more than recommended by expert 
consensus.
While women make up 58% of the total Medicaid population, they were 74% of our study 
population. Our study is consistent with previous literature in finding that women constitute 
the majority of users of opioids both alone and in combination with benzodiazepines.15 We 
found that the mean number of opioid prescriptions differed by one script per year between 
female and male opioid recipients (6.0 and 7.1 respectively); however, the annual mean 
days' supply was much lower for women than men (96.4 and 133 respectively). Despite the 
fact that men are more likely to use prescription painkillers non-medically, to abuse opioids, 
and to die from drug overdoses involving opioids,30,31 the percentage increase in the number 
of recent deaths from prescription painkillers is greater among women.32 The prevalences of 
indicators of possible misuse in this study were only slightly lower among women in this 
Medicaid population.
Limitations
Our study has several limitations. The potential inappropriate indicators have been validated 
by their association with misuse or abuse in other studies. In some cases, of course, such 
behaviors represent appropriate care for patients not misusing drugs, e.g., overlapping 
prescriptions resulting from changes in dosage or in drug type as a result of some adverse 
effect, or use of short-acting opioids for break through pain in patients receiving long-acting 
or extended release opioids. Claims data were designed to support financial transactions 
rather than to capture clinical information, and as such may suffer some inherent flaws, 
however they remain an important source of health data.33 Pharmacy claims represent filled 
prescriptions reimbursed rather than actual drug consumption and do not capture 
prescriptions paid for with cash. Prescriber information was incomplete to the extent that 
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analyses based on prescriber data would have severe limitations. Last, relying on ICD-9CM 
codes to determine the reason for a prescription is subject to error. Many conditions are 
painful but are not usually counted among common causes of pain. Type of pain might also 
have been misclassified. While these analyses are unable to determine whether patient or 
prescriber was the source of any potential prescribing or use problems, our analysis 
represents a comprehensive look at opioid use and potential inappropriate among Medicaid 
recipients in the largest fully-integrated commercial claims database in the United States, 
and they point to situations that warrant further investigation to determine causal factors.
While the majority of opioid prescriptions among this population might have been 
appropriate, a substantial number were prescribed in a manner that suggests inappropriate 
patient use or provider prescribing practice. Robust prescription opioid utilization review 
programs using integrated claims data, similar to our analyses, might reduce misuse and 
overdose risk, help improve quality of care, and reduce unnecessary health care costs.6,34 
Such programs, combined with other systematic prevention strategies such as prescription 
drug monitoring programs, that track information on controlled substance prescriptions 
filled in a state, and use of opioid prescribing guidelines may assist providers to address 
improper opioid use, reduce the risk of adverse outcomes, and improve the appropriate 
prescribing of opioid medications.
Acknowledgments
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
References
1. Paulozzi LJ. Prescription drug overdoses: a review. J Safety Res. 2012 Sep; 43(4):283–89. http://
dx.doi.org/10.1016/j.jsr.2012.08.009. [PubMed: 23127678] 
2. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 
2013 Feb; 309(7):657–9. http://dx.doi.org/10.1001/jama.2013.272. [PubMed: 23423407] 
3. Quality CfBHSa. , editor. Substance Abuse and Mental Health Services Administration. The 
DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-
Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health 
Services Administration; 2013. 
4. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-
cancer pain. Pharmacoepidemiol Drug Saf. 2009 Dec; 18(12):1166–75. http://dx.doi.org/10.1002/
pds.1833. [PubMed: 19718704] 
5. Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer 
pain. Clin J Pain. 2008 Jul-Aug;24(6):521–7. http://dx.doi.org/10.1097/AJP.0b013e318169d03b. 
[PubMed: 18574361] 
6. Parente ST, Kim SS, Finch MD, et al. Identifying controlled substance patterns of utilization 
requiring evaluation using administrative claims data. Am J Manag Care. 2004 Nov; 10(11 Pt 1):
783–90. [PubMed: 15623267] 
7. Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 
2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008 Aug 31; 
138(2):440–9. Epub 2008 Jun 10. http://dx.doi.org/10.1016/j.pain.2008.04.027. [PubMed: 
18547726] 
8. U.S. Government Accountability Office. Medicaid: fraud and abuse related to controlled substances 
identified in selected states. Washington, DC: U.S. Government Accountability Office; 2009. 
Mack et al. Page 7













9. McAdam-Marx C, Roland CL, Cleveland J, et al. Costs of opioid abuse and misuse determined from 
a Medicaid database. J Pain Palliat Care Pharmacother. 2010 Mar; 24(1):5–18. http://dx.doi.org/
10.3109/15360280903544877. [PubMed: 20345194] 
10. Braden JB, Fan MY, Edlund MJ, et al. Trends in use of opioids by noncancer pain type 2000-2005 
among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study. J Pain. 2008 
Nov; 9(11):1026–35. Epub 2008 Jul 26. http://dx.doi.org/10.1016/j.jpain.2008.06.002. [PubMed: 
18676205] 
11. Adelmann PK. Mental and substance use disorders among Medicaid recipients: prevalence 
estimates from two national surveys. Adm Policy Ment Health. 2003 Nov; 31(2):111–29. http://
dx.doi.org/10.1023/B:APIH.0000003017.78877.56. [PubMed: 14756195] 
12. Whitmire, JT.; Adams, GW. Unintentional overdose deaths in the North Carolina Medicaid 
population: prevalence, prescription drug use, and medical care services. Raleigh, NC: State 
Center for Health Statistics; 2010. 
13. Coolen P, Lima A, Savel J, et al. Overdose deaths involving prescription opioids among Medicaid 
enrollees—Washington, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009 Oct 30; 58(42):1171–
5. [PubMed: 19875978] 
14. Liu Y, Logan J, Paulozzi L, et al. Potential Misuse and Inappropriate Prescription Practices of 
Opioid Analgesics among Commercially Insured Americans. Am J Manag Care. 2013 Aug; 19(8):
648–65. [PubMed: 24304213] 
15. Campbell CI, Weisner C, Leresche L, et al. Age and gender trends in long-term opioid analgesic 
use for noncancer pain. Am J Public Health. 2010 Dec; 100(12):2541–7. Epub 2010 Aug 19. 
http://dx.doi.org/10.2105/AJPH.2009.180646. [PubMed: 20724688] 
16. Agency Medical Directors' Group (AMDG). Opioid dosing guidelines for chronic non-cancer pain: 
an educational aid to improve care and safety with opid therapy, 2010 update. Olympia, WA: 
AMDG; 2010. Available at: http://www.agencymeddirectors.wa.gov/contact.asp
17. Washington Chapter American College of Emergency Physicians. Washington Emergency 
Department Opioid Prescribing Guidelines. Seattle, WA: WCACEP; 2010. 
18. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in 
chronic noncancer pain. J Pain. 2009 Feb; 10(2):113–30. http://dx.doi.org/10.1016/j.jpain.
2008.10.008. [PubMed: 19187889] 
19. Utah Department of Health. Utah clinical guidelines on prescribing opioids for treatment of pain. 
Salt Lake City, UT: Utah Department of Health; 2009. 
20. Kahan M, Mailis-Gagnon A, Wilson L, et al. Canadian guideline for safe and effective use of 
opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general 
population. Can Fam Physician. 2011 Nov; 57(11):1257–66. e407–18. [PubMed: 22084455] 
21. New York City Department of Health and Mental Hygiene. New York City Emergency 
Department Discharge Opioid Prescribing Guidelines. New York, NY: New York City 
Department of Health and Mental Hygiene; 2013. Available at: http://www.nyc.gov/html/doh/
downloads/pdf/basas/opioid-prescribing-guidelines.pdf
22. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians 
(ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2—
guidance. Pain Physician. 2012 Jul; 15(3 Suppl):S67–116. [PubMed: 22786449] 
23. White AG, Birnbaum HG, Schiller M, et al. Analytic Models to Identify Patients at Risk for 
Prescription Opioid Abuse. Am J Manag Care. 2009 Dec; 15(12):897–906. [PubMed: 20001171] 
24. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a 
cohort study. Ann Intern Med. 2010 Jan 19; 152(2):85–92. http://dx.doi.org/
10.7326/0003-4819-152-2-201001190-00006. [PubMed: 20083827] 
25. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and 
opioid overdose-related deaths. JAMA. 2011 Apr 6; 305(13):1315–21. http://dx.doi.org/10.1001/
jama.2011.370. [PubMed: 21467284] 
26. Braden JB, Russo J, Fan MY, et al. Emergency department visits among recipients of chronic 
opioid therapy. Arch Intern Med. 2010 Sep 13; 170(16):1425–32. http://dx.doi.org/10.1001/
archinternmed.2010.273. [PubMed: 20837827] 
Mack et al. Page 8













27. Hegmann, K. Occupational medicine practice guidelines: evaluation and management of common 
health problems and functional recovery in workers. Elk Grove Village, IL: American College of 
Occupational and Environmental Medicine; 2011. 
28. Paone, D.; Dowell, D.; Heller, D. Preventing misuse of prescription opioid drugs. Long Island 
City, NY: The New York City Department of Health and Mental Hygiene; 2011. 
29. American College of Occupational and Environmental Medicine. Guidelines for the chronic use of 
opioids. Elk Grove Village, IL: ACOEM; 2011. 
30. Office of Applied Studies. , editor. Substance Abuse and Mental Health Services Administration. 
Results from the 2009 National Survey on Drug Use and Health: Summary of National Findings: 
Volume I Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health 
Services Administration; 2011. 
31. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain 
relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011 Nov 4; 60(43):1487–
92. [PubMed: 22048730] 
32. Mack KA, Jones CM, Paulozzi L. Vital Signs: Overdoses of Prescription Opioid Pain Relievers 
and Other Drugs Among Women—United States, 1999–2010. MMWR—Morbidity and Mortality 
Weekly Report. 2013 Jul 5; 62(26):537–42. [PubMed: 23820967] 
33. Tessier-Sherman B, Galusha D, Taiwo OA, et al. Further validation that claims data are a useful 
tool for epidemiologic research on hypertension. BMC Public Health. 2013 Jan 18.13:51. http://
dx.doi.org/10.1186/1471-2458-13-51. [PubMed: 23331960] 
34. Goldberg GA, Kim SS, Seifeldin R, et al. Identifying suboptimal management of persistent pain 
from integrated claims data: a feasibility study. Manag Care. 2003 Aug; 12(8 Suppl Improving 
pain):8–13. [PubMed: 13677058] 
Mack et al. Page 9














Opioid prescriptions drawn from pharmaceutical claims flow chart.
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